COVID-19 Resources

HIV and COVID-19

Q&A on COVID-19, HIV and antiretrovirals and HIV and viral hepatitis (WHO)

Programmatic and clinical guidance

New! COVID-19 and HIV: A tale of two pandemics (International AIDS Society): This brief report describes the three key ways in which the COVID-19 pandemic is impacting the HIV response, provides 10 succinct recommendations for HIV service delivery in the context of COVID-19 as well as 10 recommendations for the COVID-19 response as informed by learnings from nearly 40 years of HIV response.

New! The impact of the COVID-19 response on the supply chain, availability and cost of generic antiretroviral medicines for HIV in low- and middle-income countries (UNAIDS): This report assesses the situational landscape during mid-May 2020 surrounding the value chain of the production and distribution of generic antiretroviral medicines in LMICs and provides recommendations to governments on mitigating the risks of potential disruptions.

Interim guidance for COVID-19 and PLHIV (AIDSInfo): Review of special considerations for people living with HIV and their health care providers in the United States regarding COVID-19. The guidance offers suggestions on switching ART, appointment postponement, planning for isolation, and HIV SARS-CoV-2 co-infection management. See also interim adult ART guidance from the British HIV Association

PEPFAR Technical Guidance in Context of COVID-19 Pandemic (PEPFAR): Technical note with guidance on a range of HIV-specific, cross-cutting and health systems issues related to PEPFAR's programmes. The document is updated twice per week as the situation evolves globally. See also:

COVID-19: Considerations for Global Fund Support for HIV (Global Fund): This information note summarizes preliminary messages about the operation of Global Fund-supported HIV programmes and services, and provides guidance on adaptive prevention, testing and treatment programming.

HIV prevention

Maintaining and prioritizing HIV prevention services in the time of COVID-19 (Global HIV Prevention Working Group): This brief outlines several critical actions and temporary modifications that can be considered to ensure continued effective HIV prevention and related services in the time of COVID-19. 

Condoms and lubricants in the time of COVID-19. Sustaining supplies and people-centred approaches to meet the need in low- and middle-income countries (Global Condom Working Group): This brief for country condom programme managers and experts provides a summary of relevant actions to sustain supplies of male condoms, female condoms and lubricants, and to adjust approaches for condom promotion during the time of COVID-19.

PrEP during COVID-19 (CDC): US-based guidance for providing PrEP as an essential service when facility-based services and in-person patient-clinician contact is limited.

Models of COVID-19 impacts on HIV

The Potential Impact of the COVID-19 Epidemic on HIV, TB and Malaria in Low- and Middle-Income Countries (Imperial College London): Researchers have modelled the impact of COVID-19 on HIV, TB and malaria in low- and middle-income countries and predicted significant rises in cases and deaths. The greatest impact on HIV is estimated to be from interruption to supply and administering of ART; this could cause a 10 per cent rise in deaths over five years.

Potential effects of disruption to HIV programmes in sub-Saharan Africa caused by COVID-19: Results from multiple mathematical models (Jewell BL et al.): A modelling group convened by WHO and UNAIDS estimates that pandemic-related disruptions to HIV services for six months could cause more than 500,000 additional deaths from AIDS-related illnesses in subSaharan Africa in 2020–2021. Gains made in preventing mother-to-child HIV transmission could also be reversed.